Back to top
more

Quanterix (QTRX)

(Delayed Data from NSDQ)

$11.44 USD

11.44
555,932

-0.48 (-4.03%)

Updated Nov 15, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 48% (129 out of 250)

Industry: Medical - Products

Zacks News

Here's Why You Should Retain Henry Schein (HSIC) Stock for Now

Investors are optimistic about Henry Schein (HSIC), led by the strength of its dental business.

Orthofix's (OFIX) New Launch to Benefit the MIS Spine Market

Orthofix (OFIX) announces the commercial launch and the successful completion of the first cases in the United States with the 7D FLASH Navigation System Percutaneous Module 2.0.

Syneos Health (SYNH) Expands Catalyst Site Program to China

Syneos Health (SYNH) announces a collaboration with China's Wuhan Union Hospital, expanding clinical trial capabilities.

Integra (IART) CSS Sales Aid, Boston Recall Hurts Growth

In spite of facing foreign exchange fluctuations across its non-U.S. business, Integra (IART) is successfully broadening its international footprint.

BioSig (BSGM) Grows in Arrhythmia Care With Subscription Model

BioSig's (BSGM) subscription model for PURE EP provides electrophysiologists and cardiology departments with flexibility.

Thermo Fisher's (TMO) EXTENT Solution Makes Commercial Launch

Thermo Fisher (TMO) announces the commercial launch of the EXTENT Solution with IVDR certification.

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

Investors continue to be optimistic about Tandem Diabetes (TNDM) due to the t:slim X2 insulin pump and new product innovations.

Boston Scientific (BSX) Expands Globally Amid FX Concerns

Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.

CVS Health's (CVS) Cordavis to Focus on Biosimilar Products

CVS Health's (CVS) wholly owned subsidiary, Cordavis, is set to bring high-quality biosimilar products to the market.

NanoString (NSTG) Advances in Xenotransplantation With New Study

NanoString's (NSTG) nCounter Analysis System facilitates bulk tissue transcriptome profiling, revealing the intricacies of the immune response through the nCounter Human Organ Transplant Panel.

Myriad Genetics (MYGN) Teams Up to Assess Breast Cancer Risk

Myriad Genetics (MYGN) announces collaboration with Onsite Women's Health to develop a breast cancer risk assessment program.

Align (ALGN) Rides on Growing Invisalign Sales, New Alliances

Align Technology (ALGN) is expanding its sales and marketing by reaching new countries and regions.

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

Investors continue to be optimistic about ResMed (RMD), backed by the continued demand for digital health solutions.

Teleflex (TFX) Upgrades the Arrow ErgoPack Complete System

Teleflex's (TFX) expanded Arrow ErgoPack Complete Kit now includes Hemodialysis and Large Bore catheters.

Edwards Lifesciences (EW) Rides on TAVR Amid Rise in Costs

Edwards Lifesciences' (EW) Surgical Structural Heart business growth is driven by increased penetration of its premium RESILIA products across all regions.

Illumina (ILMN) Expands Presence in India With New Facility

Illumina (ILMN) boosts genomic capabilities in India with a new state-of-the-art Solutions Center.

Quanterix Corporation (QTRX) Reports Q2 Loss, Tops Revenue Estimates

Quanterix Corporation (QTRX) delivered earnings and revenue surprises of 55.56% and 18.75%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Quanterix (QTRX) Advances in Alzheimer's Diagnosis With LucentAD

Quanterix (QTRX) LucentAD biomarker blood test aims to assist healthcare providers in evaluating patients who show cognitive symptoms consistent with the early signs of AD.

Quanterix Corporation (QTRX) Surges 13.6%: Is This an Indication of Further Gains?

Quanterix Corporation (QTRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates

Quanterix Corporation (QTRX) delivered earnings and revenue surprises of 55.56% and 11.77%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Quanterix Corporation (QTRX) Soars 33.7%: Is Further Upside Left in the Stock?

Quanterix Corporation (QTRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Quanterix Corporation (QTRX) Reports Q4 Loss, Misses Revenue Estimates

Quanterix Corporation (QTRX) delivered earnings and revenue surprises of 5.66% and 1.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

PetIQ (PETQ) Reports Q4 Loss, Misses Revenue Estimates

PetIQ (PETQ) delivered earnings and revenue surprises of 37.50% and 4.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Insulet (PODD) Q4 Earnings and Revenues Beat Estimates

Insulet (PODD) delivered earnings and revenue surprises of 129.17% and 11.91%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Medtronic (MDT) Surpasses Q3 Earnings and Revenue Estimates

Medtronic (MDT) delivered earnings and revenue surprises of 3.17% and 2.76%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?